Clinical Trial Update: Immunoglobulin Replacement Therapy for Immunoglobulin G Subclass 2 Deficient Patients With Bronchiectasis [Phase 4]

View source ↗

Summary

Phase 4 trial investigating immunoglobulin replacement for IgG subclass 2 deficiency with bronchiectasis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchiectasis
• Immunoglobulin Subclass Deficiency

Drugs mentioned

• Immunoglobulin replacement therapy

Snippet

Sponsor: University of Edinburgh | Conditions: Bronchiectasis, Immunoglobulin Subclass Deficiency | Phase 4 | Status: WITHDRAWN